Ridgeback Capital Investments L.P. Pyxis Oncology, Inc. Transaction History
Ridgeback Capital Investments L.P.
- $560 Million
- Q4 2024
A detailed history of Ridgeback Capital Investments L.P. transactions in Pyxis Oncology, Inc. stock. As of the latest transaction made, Ridgeback Capital Investments L.P. holds 359,231 shares of PYXS stock, worth $484,961. This represents 100.0% of its overall portfolio holdings.
Number of Shares
359,231Holding current value
$484,961% of portfolio
100.0%Shares
1 transactions
Others Institutions Holding PYXS
# of Institutions
100Shares Held
24.3MCall Options Held
993KPut Options Held
42.6K-
Laurion Capital Management LP New York, NY3.63MShares$4.9 Million0.11% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.98MShares$4.02 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.79MShares$3.76 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.44MShares$3.3 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.08MShares$1.46 Million0.0% of portfolio
About Pyxis Oncology, Inc.
- Ticker PYXS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,096,400
- Market Cap $47.4M
- Description
- Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, no...